Status: Recruiting
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).
Participants needed: 70
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Apr 9, 2026Locations: 9
Eligibility criteria
Absolute neutrophil count ≥1.0 K/mcL (Note: growth factor is allowed) [+10]
Any serious medical condition, laboratory abnormality, or psychiatric illness th... [+8]